Evidence map›Paper›PMID 28192409›Full record

ArticleOncogene2017

Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

I D Tonks, P Mukhopadhyay, W A Schroder, A Sorolla, A W Mould, H Y Handoko, B Ferguson, H K Muller, P Keith, N K Hayward and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

I D TonksCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
P MukhopadhyayCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
W A SchroderCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
A SorollaSchool of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, Western Australia, Australia.
A W MouldCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
H Y HandokoCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
B FergusonCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
H K MullerDepartment of Pathology, University of Tasmania School of Medicine, Hobart, Tasmania, Australia.
P KeithCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
N K HaywardCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
G J WalkerCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
G F KayCell and molecular Biology Department, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
QIMR Berghofer Medical Research Institute · AUUniversity of Oxford · GBUniversity of Queensland · AUUniversity of Tasmania · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulation of p16INK4A is a critical event in melanoma susceptibility and progression. It is generally assumed that the major effect of loss of p16 function is mediated through the CDK-cyclin pathway via its influence on the pocket protein (PP) pRb. However, there are also two other PPs, p107 and p130, which, when phosphorylated by CDK-cyclin complexes, play a role in permitting cell progression. Cohorts of mice carrying melanocyte-specific knockouts (KOs) of various combinations of the three PPs were generated. Mice null for pRb, p107, p130 or any combination of double mutants did not develop melanoma. Surprisingly, melanocyte-specific loss of all three PPs facilitated melanoma development (median age of onset 308 days, penetrance 40% at 1 year). Tumorigenesis was exacerbated by Trp53 co-deletion (median age of onset 275 days, penetrance 82% at 1 year), with cell culture studies indicating that this difference may result from the apoptotic role of Trp53. Melanomas in PP;Trp53-deficient mice lacked either Ras or Braf mutations, and hence developed in the absence of constitutive MAPK pathway activation. The lag period between induction of total PP or PP/Trp53 KO and melanoma development indicates that additional genetic or epigenetic alterations may account for neoplastic progression. However, exome sequencing of PP;Trp53 KO melanomas failed to reveal any additional recurrent driver mutations. Analysis of the putative mutation signature of the PP;Trp53 KO melanomas suggests that melanocytes are primed for transformation via a mutagenic mechanism involving an excess of T>G substitutions, but not involving a preponderance of C>T substitutions at CpG sites, which is the case for most spontaneous cancers not driven by a specific carcinogen. In sum, deregulation of all three PPs appears central to neoplastic progression for melanoma, and the customary reference to the p16

Indexed as

MAP Kinase Signaling SystemAnimalsCell Transformation, NeoplasticHumansMelanocytesMiceMice, KnockoutTumor Suppressor Protein p53Tumor Suppressor Protein p53

Identifiers

PMID28192409
OpenAlexW2588401657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.